The DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.
Playing dirty
Open accessOverview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Network biology: understanding the cell's functional organization
Barabási, A.-L., & Oltvai, Z. N. (2004) · Nature Reviews Genetics · doi:10.1038/nrg1272 · Cited by 7,903
Joensuu, H., Roberts, P. J., Sarlomo-Rikala, M., Andersson, L. C., Tervahartiala, P., Tuveson, D., Silberman, S. L., Capdeville, R., Dimitrijevic, S., Druker, B., et al. (2001) · New England Journal of Medicine · doi:10.1056/nejm200104053441404 · Cited by 2,037
Roth, B. L., Sheffler, D. J., & Kroeze, W. K. (2004) · Nature Reviews Drug Discovery · doi:10.1038/nrd1346 · Cited by 1,155
United States Food and Drug Administration Drug Approval Summary
Cohen, M. H., Williams, G. A., Sridhara, R., Chen, G., McGuinn, W. D., Morse, D., Abraham, S., Rahman, A., Liang, C., Lostritto, R., et al. (2004) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-03-0564 · Cited by 503
Knockouts model the 100 best-selling drugs—will they model the next 100?
Zambrowicz, B. P., & Sands, A. T. (2003) · Nature Reviews Drug Discovery · doi:10.1038/nrd987 · Cited by 393
Promiscuous drugs compared to selective drugs (promiscuity can be a virtue)
Mencher, S. K., & Wang, L. G. (2005) · BMC Clinical Pharmacology · doi:10.1186/1472-6904-5-3 · Cited by 206
Cited by
Targeting cancer cells by ROS-mediated mechanisms: a radical therapeutic approach?
Trachootham, D., Alexandre, J., & Huang, P. (2009) · Nature Reviews Drug Discovery · doi:10.1038/nrd2803 · Cited by 5,452
Therapeutic Roles of Curcumin: Lessons Learned from Clinical Trials
Gupta, S. C., Patchva, S., & Aggarwal, B. B. (2013) · The AAPS Journal · doi:10.1208/s12248-012-9432-8 · Cited by 2,110
Multi-target-Directed Ligands To Combat Neurodegenerative Diseases
Cavalli, A., Bolognesi, M. L., Minarini, A., Rosini, M., Tumiatti, V., Recanatini, M., & Melchiorre, C. (2008) · Journal of Medicinal Chemistry · doi:10.1021/jm7009364 · Cited by 1,152
Trachootham, D., Zhou, Y., Zhang, H., Demizu, Y., Chen, Z., Pelicano, H., Chiao, P. J., Achanta, G., Arlinghaus, R. B., Liu, J., et al. (2006) · Cancer Cell · doi:10.1016/j.ccr.2006.08.009 · Cited by 1,080
The co-evolution of host cationic antimicrobial peptides and microbial resistance
Peschel, A., & Sahl, H.-G. (2006) · Nature Reviews Microbiology · doi:10.1038/nrmicro1441 · Cited by 1,062
The Connectivity Map: A new tool for biomedical research
Lamb, J. (2007) · Nature Reviews Cancer · doi:10.1038/nrc2044 · Cited by 945
Drugs, their targets and the nature and number of drug targets
Imming, P., Sinning, C., & Meyer, A. (2006) · Nature Reviews Drug Discovery · doi:10.1038/nrd2132 · Cited by 839
Global mapping of pharmacological space
Paolini, G. V., Shapland, R. H. B., van Hoorn, W. P., Mason, J. S., & Hopkins, A. L. (2006) · Nature Biotechnology · doi:10.1038/nbt1228 · Cited by 811
Mechanisms of Disease: oncogene addiction—a rationale for molecular targeting in cancer therapy
Weinstein, I. B., & Joe, A. K. (2006) · Nature Clinical Practice Oncology · doi:10.1038/ncponc0558 · Cited by 705
The Lipophilic Bullet Hits the Targets: Medicinal Chemistry of Adamantane Derivatives
Wanka, L., Iqbal, K., & Schreiner, P. R. (2013) · Chemical Reviews · doi:10.1021/cr100264t · Cited by 696
SuperTarget and Matador: resources for exploring drug-target relationships
Gunther, S., Kuhn, M., Dunkel, M., Campillos, M., Senger, C., Petsalaki, E., Ahmed, J., Urdiales, E. G., Gewiess, A., Jensen, L. J., et al. (2007) · Nucleic Acids Research · doi:10.1093/nar/gkm862 · Cited by 647
“Even if the medical effect has been explained by a certain molecular interaction, most drugs interact with several additional targets, which may either strengthen the therapeutic effect or cause unwanted adverse drug effects ( 2 ).”
BackgroundDrug–target interaction prediction: databases, web servers and computational models
Chen, X., Yan, C. C., Zhang, X., Zhang, X., Dai, F., Yin, J., & Zhang, Y. (2016) · Briefings in Bioinformatics · doi:10.1093/bib/bbv066 · Cited by 658
Drug–target interaction prediction by random walk on the heterogeneous network
Chen, X., Liu, M.-X., & Yan, G.-Y. (2012) · Molecular BioSystems · doi:10.1039/c2mb00002d · Cited by 533
Can we rationally design promiscuous drugs?
HOPKINS, A., MASON, J., & OVERINGTON, J. (2006) · Current Opinion in Structural Biology · doi:10.1016/j.sbi.2006.01.013 · Cited by 469
León, R., Garcia, A. G., & Marco‐Contelles, J. (2013) · Medicinal Research Reviews · doi:10.1002/med.20248 · Cited by 440
Yu, H., Chen, J., Xu, X., Li, Y., Zhao, H., Fang, Y., Li, X., Zhou, W., Wang, W., & Wang, Y. (2012) · PLoS ONE · doi:10.1371/journal.pone.0037608 · Cited by 423
Ezzat, A., Wu, M., Li, X.-L., & Kwoh, C.-K. (2019) · Briefings in Bioinformatics · doi:10.1093/bib/bby002 · Cited by 314
Metz, J. T., Johnson, E. F., Soni, N. B., Merta, P. J., Kifle, L., & Hajduk, P. J. (2011) · Nature Chemical Biology · doi:10.1038/nchembio.530 · Cited by 311
Chemokine receptor antagonists: overcoming developmental hurdles
Horuk, R. (2009) · Nature Reviews Drug Discovery · doi:10.1038/nrd2734 · Cited by 303
Transient protein-protein interactions
Acuner Ozbabacan, S. E., Engin, H. B., Gursoy, A., & Keskin, O. (2011) · Protein Engineering Design and Selection · doi:10.1093/protein/gzr025 · Cited by 264
Active-learning strategies in computer-assisted drug discovery
Reker, D., & Schneider, G. (2015) · Drug Discovery Today · doi:10.1016/j.drudis.2014.12.004 · Cited by 261
Multi-Target Drugs: The Trend of Drug Research and Development
Lu, J.-J., Pan, W., Hu, Y.-J., & Wang, Y.-T. (2012) · PLoS ONE · doi:10.1371/journal.pone.0040262 · Cited by 259
A safe lithium mimetic for bipolar disorder
Singh, N., Halliday, A. C., Thomas, J. M., Kuznetsova, O. V., Baldwin, R., Woon, E. C. Y., Aley, P. K., Antoniadou, I., Sharp, T., Vasudevan, S. R., et al. (2013) · Nature Communications · doi:10.1038/ncomms2320 · Cited by 258
Metadata
- Authors
- Frantz, S.
- Venue
- Nature
- Published
- 2005-10-12
- Volume
- 437
- Issue
- 7061
- Pages
- 942-943
- ISSN
- 0028-0836 (ISSN-L)
- 1476-4687
- OpenAlex
- W2015393683
- Cited by
- 322
- References
- 6
- Type
- other
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.